Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-643
Closed -$200K 94
2025
Q1
$200K Buy
+643
New +$190K 0.04% 213
2024
Q3
Sell
-544
Closed -$170K 234
2024
Q2
$170K Buy
+544
New +$160K 0.04% 219
2023
Q3
Sell
-1,122
Closed -$249K 175
2023
Q2
$249K Sell
1,122
-107
-9% -$24.8K 0.07% 158
2023
Q1
$297K Sell
1,229
-32
-3% -$7.86K 0.08% 142
2022
Q4
$331K Buy
1,261
+8
+0.6% +$2.14K 0.1% 135
2022
Q3
$282K Buy
1,253
+9
+0.7% +$2.18K 0.09% 140
2022
Q2
$303K Buy
1,244
+9
+0.7% +$2.21K 0.09% 139
2022
Q1
$299K Buy
+1,235
New +$284K 0.08% 142
2019
Q4
Sell
-1,045
Closed -$202K 148
2019
Q3
$202K Buy
+1,045
New +$201K 0.07% 139
2019
Q1
Sell
-1,086
Closed -$211K 139
2018
Q4
$211K Buy
1,086
+40
+4% +$7.8K 0.08% 129
2018
Q3
$217K Sell
1,046
-48
-4% -$9.46K 0.08% 130
2018
Q2
$202K Buy
+1,094
New +$194K 0.08% 132
2017
Q4
Sell
-1,088
Closed -$203K 129
2017
Q3
$203K Buy
+1,088
New +$193K 0.08% 122
2016
Q2
Sell
-1,357
Closed -$203K 112
2016
Q1
$203K Buy
1,357
+3
+0.2% +$446 0.1% 105
2015
Q4
$220K Sell
1,354
-270
-17% -$42.4K 0.12% 95
2015
Q3
$225K Buy
1,624
+2
+0.1% +$315 0.12% 91
2015
Q2
$249K Sell
1,622
-225
-12% -$36K 0.13% 87
2015
Q1
$295K Buy
1,847
+51
+3% +$8.03K 0.15% 82
2014
Q4
$286K Buy
+1,796
New +$280K 0.15% 81

Other funds holding AMGN

The Family Firm's AMGN Position: Q2 2025 in Review

The Family Firm sold out of Amgen (AMGN) in Q2 2025, closing a stake of 643 shares — an estimated $200K sold.

The Family Firm first reported a position in AMGN in Q4 2014 and held it in 19 quarters. The position peaked at $331K in Q4 2022. 2,852 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.

  • The Family Firm reported no remaining Amgen position as of Q2 2025 after selling out during the quarter.
  • The Family Firm sold 643 Amgen shares in Q2 2025, an estimated $200K.
  • The Family Firm first reported a position in Amgen in Q4 2014 and held it in 19 quarters.
  • The Family Firm's Amgen position peaked at $331K in Q4 2022.
  • 2,852 funds tracked by Wall St. Rank held Amgen as of Q2 2025.

Based on The Family Firm's 13F filing for Q2 2025, filed 8 Aug 2025.